Journey Medical (DERM) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$68.2M

Revenue (quarter)

$18.5M

Revenue growth (year over year)

+23.33%

Gross profit (trailing twelve months)

$44.6M

Gross margin

65.45%

Net income (trailing twelve months)

−$6.1M

Net income (quarter)

−$312,000.00

Net income growth (year over year)

+91.78%

Net margin

−8.95%

Return on equity

−23.77%

EPS (trailing twelve months)

−$0.22

Book value per share

$1.16

P/E (trailing twelve months)

—

Price to book

5.30

Debt to assets

67.35%

Payout ratio

—

Dividend yield

—

Company profile

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

• Is Journey Medical (DERM) profitable?

  No. Journey Medical reported a net loss of $6.1M over the trailing twelve months.

• How much revenue does Journey Medical (DERM) make?

  Journey Medical generated $68.2M in revenue over the trailing twelve months, up 23.33% year over year.

• How do I buy stock in Journey Medical (DERM)?

  DERM trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.